Loading...

VGN

VGN

EVOGENE LTD

(EVGN)

2024 6-K

Financial Results Announced

5 Mar '26

CEO Letter Issued

25 Feb '26

Warrant Inducement Agreement

11 Feb '26

Licensing Agreement

4 Feb '26

Management Change

15 Jan '26

Management Change

30 Dec '25

Quarterly Financial Results

20 Nov '25

Financial Report

30 Sep '25

Investor Presentation

10 Sep '25

Quarterly Financial Results

19 Aug '25

Shareholder Approval

18 Aug '25

Annual Meeting Adjourned

11 Aug '25

Updated Proxy Card

17 Jul '25

Transaction Completion

8 Jul '25

Annual Meeting Notification

17 Jun '25

Management Change

5 Jun '25

Quarterly Results

21 May '25

Subsidiary Acquisition

21 Apr '25

Quarterly Results

6 Mar '25

Board Changes

6 Mar '25

Shareholder Approval

12 Feb '25

Meeting Adjourned

5 Feb '25

Management Change

15 Jan '25

Special Meeting Notice

30 Dec '24

Licensing Agreement Termina...

27 Nov '24

Quarterly Results Report

21 Nov '24

Management Changes

17 Sep '24

Financial Filing Report

16 Sep '24

Securities Offering

23 Aug '24

Quarterly Results Report

22 Aug '24

Compliance Restored

12 Aug '24

Share Split Announcement

23 Jul '24

New Order Received

25 Jun '24

Management Change

20 Jun '24

Shareholder Approval

17 Jun '24

AGM Adjourned

6 Jun '24

Filing Summary

29 May '24

Clinical Trial Update

23 May '24

Financial Results Release

23 May '24

Annual Meeting Notice

30 Apr '24

New Partnership Formed

2 Apr '24

Sales Agreement Executed

28 Mar '24

Nasdaq Notification

20 Mar '24

Financial Results Announced

7 Mar '24

Management Change

22 Feb '24

Bayer Collaboration

21 Feb '24

Trial Completion Report

17 Jan '24

Investor Presentation

9 Jan '24

External Links:

SEC

Evogene Ltd. submitted a Form 6-K to the SEC on September 16, 2024, providing unaudited financial statements and an operating review for the six months ending June 30, 2024.

AI Assistant

EVOGENE LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.